Stryker Corporation $SYK Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. reduced its position in Stryker Corporation (NYSE:SYK – Free Report) by 19.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,892 shares of the medical technology company’s stock after selling 5,585 shares during the period. Hantz Financial Services Inc.’s holdings in Stryker were worth $6,304,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pensioenfonds Rail & OV purchased a new stake in Stryker during the third quarter valued at about $5,739,000. IFG Advisory LLC increased its stake in Stryker by 1.7% during the third quarter. IFG Advisory LLC now owns 3,040 shares of the medical technology company’s stock worth $837,000 after acquiring an additional 52 shares during the last quarter. Optas LLC increased its stake in Stryker by 21.7% during the third quarter. Optas LLC now owns 898 shares of the medical technology company’s stock worth $247,000 after acquiring an additional 160 shares during the last quarter. Act Two Investors LLC raised its holdings in shares of Stryker by 13.8% in the 3rd quarter. Act Two Investors LLC now owns 57,147 shares of the medical technology company’s stock worth $15,738,000 after purchasing an additional 6,930 shares during the period. Finally, Danske Bank A S raised its holdings in shares of Stryker by 4.5% in the 3rd quarter. Danske Bank A S now owns 218,478 shares of the medical technology company’s stock worth $60,167,000 after purchasing an additional 9,421 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.2%

Shares of NYSE SYK opened at $310.30 on Tuesday. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The company has a market cap of $118.13 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.14 and a beta of 0.78. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock has a fifty day moving average price of $292.44 and a 200 day moving average price of $322.36.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period last year, the business earned $3.19 earnings per share. Research analysts anticipate that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Insider Activity

In related news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 550,000 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the transaction, the director directly owned 1,701,375 shares in the company, valued at $553,491,315. This trade represents a 24.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 600,441 shares of company stock valued at $196,075,917 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. JPMorgan Chase & Co. decreased their target price on Stryker from $350.00 to $340.00 and set an “overweight” rating for the company in a report on Friday, October 30th. Citigroup reissued a “market outperform” rating on shares of Stryker in a research report on Friday, October 30th. Evercore raised their price target on shares of Stryker from $335.00 to $355.00 in a report on Wednesday, October 28th. Finally, Johnson Rice cut shares of Stryker to a “hold” rating in a research report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $342.19.

Read Our Latest Analysis on Stryker

About Stryker

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Read More

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.